Literature DB >> 34825961

Severe aplastic anemia in a patient with erythropoietic protoporphyria successfully treated by avatrombopag.

Ziming Jiang1, Xianyong Jiang2, Miao Chen3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34825961     DOI： 10.1007/s00277-021-04726-2

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  6 in total

Review 1.  How I treat acquired aplastic anemia.

Authors:  Andrea Bacigalupo
Journal:  Blood       Date:  2017-01-17       Impact factor: 22.113

2.  Myelodysplastic syndrome terminating in erythropoietic protoporphyria after 15 years of aplastic anemia.

Authors:  T Shirota; H Yamamoto; S Hayashi; H Fujimoto; Y Harada; T Hayashi
Journal:  Int J Hematol       Date:  2000-07       Impact factor: 2.490

Review 3.  Liver disease and erythropoietic protoporphyria: a concise review.

Authors:  María José Casanova-González; María Trapero-Marugán; E Anthony Jones; Ricardo Moreno-Otero
Journal:  World J Gastroenterol       Date:  2010-09-28       Impact factor: 5.742

Review 4.  Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management.

Authors:  Manisha Balwani
Journal:  Mol Genet Metab       Date:  2019-01-24       Impact factor: 4.797

Review 5.  Current evidence and the emerging role of eltrombopag in severe aplastic anemia.

Authors:  Beatrice Drexler; Jakob Passweg
Journal:  Ther Adv Hematol       Date:  2021-03-03

Review 6.  Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.

Authors:  Jeffrey Gilreath; Mimi Lo; Joseph Bubalo
Journal:  Drugs       Date:  2021-06-23       Impact factor: 9.546
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.